Business Wire

Amazon and National Safety Council Create First-of-its-Kind Partnership to Solve the Most Common Workplace Injury in the U.S.

10.6.2021 15:00:00 EEST | Business Wire | Press release

Share

Today Amazon (NASDAQ:AMZN) and National Safety Council (NSC) announced a five-year partnership to invent new ways to prevent the largest category of workplace injuries in the U.S., musculoskeletal disorders (MSDs). Amazon and NSC have been working together for months on this first-of-its-kind collaboration.

“Through this partnership we’ll be able to solve problems that people face every day so they can live their fullest lives,” said Lorraine Martin, president and CEO of National Safety Council. “Going to work should be a positive, rewarding, and safe experience. We are grateful for the generous support of Amazon to help companies around the world solve this important issue while fueling our nonprofit mission to keep employees safe in the workplace.”

"As a member of Amazon’s onsite safety team, my goal is to do everything I can to keep my fellow employees healthy at work so we all go home safe to our friends and families," said Chelsea Weimer, an hourly employee at Amazon’s fulfillment center in Baltimore, MD. "Amazon has a high standard for safety; this partnership is more proof of that and I can't wait to see the work that's done to help decrease MSDs."

The partnership will aim to prevent MSDs across a variety of industries by engaging key stakeholders, conducting research, inventing new technology and processes, and scaling the results. The collaboration is made possible by Amazon’s $12 million contribution, the largest corporate contribution in the history of NSC, and will include five key components:

Advisory Council: Establishing an international advisory council to bring together safety experts, corporations, and researchers in public and private sectors. The advisory council will work together to review the most promising approaches to MSD prevention, shape the development of partnership components, and engage external parties on MSD prevention.

Pioneering Research: Conducting research utilizing next-generation artificial intelligence, natural language processing, and machine learning tools to explore current and future MSD innovations and trends. The research will be available to all industries to explore and glean insights.

Small Business and University Grants: Providing grants to small businesses, universities, and university students. These grants will fund research and innovation that help companies of all sizes achieve impact.

Innovation Challenge: Incubating and fostering innovative and practical solutions to address MSDs through Innovation Challenge competitions. These competitions will bring together experts to collaborate, iterate, and share techniques and ideas.

Industry Call to Action – The MSD Pledge: Amazon and NSC will share solutions discovered throughout the partnership to inspire change through the creation of The MSD Pledge and a call on other companies to also join the effort to:

  • Track proactive indicators of injuries to ensure proper risk mitigation and implement prevention strategies based on data.
  • Implement an MSD prevention program that includes educating employees and employers about injury prevention.
  • Embrace and drive forward innovative solutions to prevent MSDs and share best practices with other organizations worldwide.

The partnership kicks off in June during National Safety Month and in its first year will focus on launching the advisory council, identifying research partners, analyzing existing data, and developing the grant and Innovation Challenge programs.

“Nothing is more important than the safety of our employees, and this partnership will allow us to dive deep into the best way to reduce MSDs,” said Heather MacDougall, Amazon’s vice president of worldwide workplace health and safety. “National Safety Council has a long history of advancing safe practices in the workplace, and we look forward to working alongside them as well as many other businesses, experts, and students around the world to innovate and solve for this important issue.”

The NSC collaboration is another step in Amazon’s long-term mission to be Earth’s Safest Place to Work, which includes an investment of over $300 million into safety projects in 2021, and a goal to cut its recordable incident rate by 50% by 2025. Every day, Amazon works closely with health and safety experts, conducts thousands of safety inspections inside every building, and actively seeks employee feedback on how to improve their well-being at work. To see inside Amazon’s workplace and learn more about its team and technology, sign up for a fulfillment center tour at www.amazon.com/FCtours.

National Safety Council is America’s leading nonprofit safety advocate—and has been for over 100 years. As a mission-based organization, it works to eliminate the leading causes of preventable death and injury, focusing its efforts on the workplace, roadway, and impairment. It creates a culture of safety to keep people safer not only at work, but also beyond the workplace.

To learn more about employee safety at Amazon, visit www.amazon.com/employee-safety.

To learn more about the partnership, visit www.nsc.org/amazonpartnership.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye